247 related articles for article (PubMed ID: 23129327)
1. Role of dopamine D(2) receptors for antipsychotic activity.
Ginovart N; Kapur S
Handb Exp Pharmacol; 2012; (212):27-52. PubMed ID: 23129327
[TBL] [Abstract][Full Text] [Related]
2. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
3. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
[TBL] [Abstract][Full Text] [Related]
4. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
[TBL] [Abstract][Full Text] [Related]
5. Activation of dopamine D2 receptors in the CNS inhibits sympathetic cutaneous vasomotor alerting responses (SCVARs), contributing to clozapine's SCVAR-inhibiting action.
Blessing WW; Ootsuka Y
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):328-36. PubMed ID: 17055139
[TBL] [Abstract][Full Text] [Related]
6. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions.
Gross G; Drescher K
Handb Exp Pharmacol; 2012; (213):167-210. PubMed ID: 23027416
[TBL] [Abstract][Full Text] [Related]
7. [Critical review of mechanisms of action of second-generation antipsychotic drugs].
Miyamoto S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2006 Nov; 26(5-6):199-208. PubMed ID: 17240845
[TBL] [Abstract][Full Text] [Related]
8. The complexity of the dopaminergic synapses and their modulation by antipsychotics.
Leuner K; Müller WE
Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S15-20. PubMed ID: 16508891
[TBL] [Abstract][Full Text] [Related]
9. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.
Iyo M; Tadokoro S; Kanahara N; Hashimoto T; Niitsu T; Watanabe H; Hashimoto K
J Clin Psychopharmacol; 2013 Jun; 33(3):398-404. PubMed ID: 23609386
[TBL] [Abstract][Full Text] [Related]
10. [Functional role of dopamine D4 receptor in schizophrenia].
Semba J
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):13-20. PubMed ID: 15027326
[TBL] [Abstract][Full Text] [Related]
11. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
[TBL] [Abstract][Full Text] [Related]
12. Combined alpha 2-adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle.
Ballmaier M; Zoli M; Mazzoncini R; Gennarelli M; Spano F
Psychopharmacology (Berl); 2001 Dec; 159(1):105-10. PubMed ID: 11797077
[TBL] [Abstract][Full Text] [Related]
13. [Functional role of dopamine D3 receptor in schizophrenia].
Semba J
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325
[TBL] [Abstract][Full Text] [Related]
14. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
Kuroki T; Nagao N; Nakahara T
Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D2 receptors as treatment targets in schizophrenia.
Seeman P
Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
Howes OD; Egerton A; Allan V; McGuire P; Stokes P; Kapur S
Curr Pharm Des; 2009; 15(22):2550-9. PubMed ID: 19689327
[TBL] [Abstract][Full Text] [Related]
18. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
Miyamoto S; Duncan GE; Marx CE; Lieberman JA
Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
[TBL] [Abstract][Full Text] [Related]
19. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
[TBL] [Abstract][Full Text] [Related]
20. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
Millan MJ
J Pharmacol Exp Ther; 2000 Dec; 295(3):853-61. PubMed ID: 11082417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
